More than 900 US medical cannabis dispensaries have become the first operators in the country to hold federal registration, marking the first tangible change for operators since April’s partial rescheduling order.
The world’s largest clinical trial on cannabidiol (CBD) as a treatment for insomnia has been given the green light to complete its Phase III trial, transforming the fortunes of Avecho Biotechnology, and potentially the lives of insomnia sufferers worldwide.
On Monday (June 29), the most consequential hearing in the history of US cannabis policy began proceedings, as the DEA and the seven invited representatives made their opening statements.
On June 29, 2026, one of the most consequential hearings in the history of US cannabis policy, the crucial DEA Administrative Law Judge (ALJ) hearing that could determine whether adult-use cannabis joins state-licensed medical cannabis on Schedule III of the Controlled Substances Act, begins proceedings.
Cannabis stocks have, for the last five years or so, represented one of, if not the worst-performing, niche categories on any exchange.
Having spent over 30 years in advisory roles in financial markets prior to entering the cannabinoid industry, I lived through many hyperbolic boom/bust market cycles.
For much of the past five years, the cannabis industry has been defined by disappointment.
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to VER-01, the flagship full-spectrum cannabis drug from Munich-based Vertanical, putting it in prime position to become the first FDA-approved cannabis-derived medicine for pain, and only the second such approval since Epidiolex in 2018.
Today’s cannabis news is dominated by rescheduling momentum, with operators racing to secure DEA Schedule III status even as the White House raises fresh concerns over high-potency products, while the UK, Brazil and Idaho underline how rapidly access is broadening on multiple fronts.
